Company Overview

Corporate Profile
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, for the treatment of sickle cell disease and idiopathic pulmonary fibrosis.
Stock Quote
GBT (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$32.55
Change (%) Stock is Up 0.55 (1.72%)
Volume674,181
Data as of 10/20/17 4:00 p.m. ET
Refresh quote
Featured Events
Webcast
GBT at the 2016 American Society of Hematology (ASH) Annual Meeting (Replay)
12/05/16 at 12:15 p.m. PT
ASH 2016 Poster: Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor
ASH 2016 Poster: The 9-Item Sickle Cell Disease Severity Measure (SCDSM): A Novel Measure of Daily SCD Symptom Severity Developed to Assess Benefit of GBT440, an Experimental HbS Polymerization Inhibitor
ASH 2016 Poster: Absorption, Metabolism, and Excretion of GBT440, a Novel Hemoglobin S (HbS) Polymerization Inhibitor for the Treatment of Sickle Cell Disease (SCD), in Healthy Male Subjects
Corporate Presentation
Download Documentation Corporate Presentation (September 2017)
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
10/11/17Global Blood Therapeutics Announces Presentation of New Data Showing Positive Effect of GBT440 on Sickle Cell Disease Patient with Variant Genotype
First Presentation of Data Specifically Focused on HbSC Genotype Data Presented at Academy for Sickle Cell and Thalassemia (ASCAT) 11th Annual Conference SOUTH SAN FRANCISCO, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the presentation of a case study highlighting the effect of GBT440 on markers of anemia and hemolysis (the destruction of red blood cells) in a patient with sickle cell disease (SCD) with the variant HbSC genot... 
Printer Friendly Version
10/03/17Global Blood Therapeutics Announces Upcoming Presentations of GBT440 Data at Two Sickle Cell Disease Meetings in October
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that new data supporting its GBT440 program in sickle cell disease (SCD) will be presented in October at the Academy for Sickle Cell and Thalassemia (ASCAT) 11th Annual Conference in London and the Sickle Cell Disease Association of America (SCDAA) 45th Annual National Convention in Atlanta. "Each of the two GBT440 presentations in October will highlight an importan... 
Printer Friendly Version
09/26/17Global Blood Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on September 25, 2017, the compensation committee of the Company’s board of directors granted one new employee an option to purchase 15,000 shares of the Company’s common stock with a per share exercise price of $28.25, the closing trading price on the grant date, and a restricted stock unit award for 10,000 shares of the Company’s common stock, in each case u... 
Printer Friendly Version
09/06/17Global Blood Therapeutics To Convene Sickle Cell Disease Influencers at Annual Sickle Cell Disease (SCD) Therapeutics Conference
Healthcare Providers, Patient Advocates, Government Agencies and Industry Will Discuss Critical Issues Facing SCD Community During National Sickle Cell Disease Awareness Month Livestream of Conference Will Be Available Through Collaboration with Sickle Cell Warriors SOUTH SAN FRANCISCO, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will host the Annual Sickle Cell Disease (SCD) Therapeutics Conference, which will take... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Global Blood Therapeutics Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.